Baseline characteristics of patients
| Variable | CLA-ST (n=125) | LEV250-ST (n=125) | LEV500-ST (n=125) |
| Age, years, range (median) | 18–74 (48) | 18–78 (48) | 18–80 (47) |
| Male/female | 50/75 | 51/74 | 58/67 |
| Upper endoscopy | 60/125 | 81/125 | 78/125 |
| Peptic ulcer | 5/60 (8.3%) | 8/81 (9.8%) | 6/78 (7.7%) |
| Mild mixed gastritis | 47/60 (78.4%) | 62/81 (76.6%) | 60/78 (76.9%) |
| Antrum predominant gastritis | 7/60 (11.6%) | 12/81 (14.8%) | 11/78 (14.2%) |
| Corpus predominant gastritis | 6/60 (10%) | 7/81 (8.6%) | 7/78 (8.9%) |
| Intestinal metaplasia | 9/60 (15%) | 13/81 (16%) | 12/78 (15.3%) |
CLA, clarithromycin; LEV250, levofloxacin 250 mg; LEV500, levofloxacin 500 mg; ST, sequential therapy.